Pomalidomide in combination with low-dose dexamethasone has shown a 30% overall response rate in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both, including those with prior transplant, according to the results presented at the 2012 Annual Meeting of the American Society of Clinical Oncology. These data suggest that lack of a cross-resistance between pomalidomide and lenalidomide and confirm activity not only in patients refractory to bortezomib but also those for whom transplant has failed.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with multiple myeloma.
After participating in this educational activity, participants should be better able to:
- Compare the efficacy and safety of regimens that contain an immunomodulatory agent and a proteasome inhibitor as initial treatment of newly diagnosed multiple myeloma (MM).
- Assess the response rates for pomalidomide in combination with low-dose dexamethasone in refractory MM patients unresponsive to transplantation.
Click Next to begin the activity.